Published in: Annals of Medicine
Authors: Aki Furusawa ,Seiichiro Takao, Motofumi Suzuki, Makoto Kano, Hiroshi Yamamoto, Miyu Kano, Peter Choyke, Hisataka Kobayashi
Near-infrared photoimmunotherapy (NIR-PIT) typically employs EGFR-receptor for targeting. In this study, EpCAM receptor targeting was investigated as a potential for expanding therapeutic potential of NIR-PIT to cancers that lack or have low levels of EGFR. Antibody Edrecolomab conjugated to IR700 was evaluated for breast cancer in vitro and in vivo using immunocompetent mice. Studies showed effective cell killing when activated with ML7710 laser, as well as robust activation of CD8+ T cells with 50% complete remission rate.
